Is Metronidazole Cream or Gel Better for Rosacea?

The one randomized trial that directly compared metronidazole gel and cream for rosacea found a modest edge for gel in reducing inflammatory lesions, but the difference was not large enough to declare one formulation clearly superior. Across broader reviews, results have been described as fairly consistent regardless of formulation. In practice, the choice between cream and gel often comes down to your skin type, your tolerance for specific side effects, and how each product feels on your face.

What the Head-to-Head Trial Actually Found

Only one well-designed clinical trial has put metronidazole cream and gel side by side in the same study population. At ten weeks, patients using the gel saw a median reduction in inflammatory lesion counts of about 67%, compared with roughly 58% for those using the cream. Both formulations handily beat the vehicle-only placebo group, which managed around 46%.¹ That gap of about nine percentage points is real, but it is not the kind of dramatic difference that would make cream a poor option for someone who prefers it.

A broader review that pooled results from multiple trials of all metronidazole formulations found that the mean number of papules and pustules dropped by between 48% and 65% across studies, and those reductions were “fairly consistent regardless of formulation, strength, or application frequency.”² So while the single head-to-head trial tips slightly toward gel, the body of evidence as a whole suggests that cream, gel, and lotion all reduce rosacea bumps within a similar range.

How the Vehicle Changes Drug Delivery

The vehicle, meaning the base in which the active drug is suspended, is not just a cosmetic detail. Research using human cadaver skin showed that metronidazole penetrated skin most with cream formulations and least with gel, with lotion falling in between.³ The same research group concluded that the delivery vehicle may actually be more important than the active drug concentration in determining how much metronidazole reaches the skin.⁴

That sounds like it should favor cream, but penetration speed and total absorption are not the whole story. A more recent formulation study found that metronidazole released faster from gel than from cream, and by seven days the total amount that had permeated through intact skin was essentially the same for both.⁵ What this means in practical terms is that cream may slowly release more drug into deeper skin layers over time, while gel delivers a quicker initial dose at the surface. Neither approach is inherently better; rosacea involves inflammation in varying skin depths, and both delivery patterns can address it.

Side Effects and How Each Formulation Feels

Topical metronidazole in general is well tolerated. Stinging, dryness, burning, and itching are each reported by roughly 2% or fewer of patients.² But the specific side-effect profile shifts depending on whether you use cream or gel, and for some people that shift matters a lot.

An indirect comparison of patient-reported side effects found that metronidazole gel users more frequently reported skin dryness (about 26% reported it, compared with 15% of patients on azelaic acid foam), while metronidazole cream users were more likely to mention burning, itching, and redness.⁶ This pattern makes intuitive sense. Gels typically contain alcohol or other solvents that evaporate quickly and can strip moisture, leaving skin tight and dry. Creams contain emollients and oils that help maintain the skin’s moisture but can feel heavier and occasionally irritate through occlusion or fragrance ingredients.

On the encouraging side, a study that tracked skin barrier function in patients using a 1% metronidazole gel found no disruption of the barrier and even a trend toward increased skin hydration that nearly reached statistical significance.⁷ So while individual reports of dryness are common enough, the gel does not appear to structurally damage the skin’s protective layer.

Matching the Formulation to Your Skin

When surveys ask rosacea patients what bothers them most about their topical treatment, efficacy tops the list at about 65%, followed by skin dryness at around 18%, and burning sensation at about 9%.⁸ Since both cream and gel perform in roughly the same efficacy range, those secondary concerns about dryness and burning often end up being the tiebreaker.

A reasonable approach is to let your baseline skin condition guide the choice. If you already tend toward oily skin or live in a humid climate, gel is typically the better bet. It absorbs quickly, leaves no visible residue, and sits well under sunscreen or makeup. If your skin leans dry or your rosacea includes a lot of flaking and tightness, cream offers built-in moisture that the gel does not. People whose main complaint is burning and stinging might also lean toward gel, since the cream vehicle was more frequently associated with those sensations in comparative data. People who find dryness intolerable should probably favor cream.

There is no universal right answer, and dermatologists routinely tell patients to try one formulation and switch if it doesn’t suit them. The active ingredient is the same; only the wrapper changes.

How Metronidazole Compares to Other Topical Options

Even once you settle the cream-versus-gel question, it is worth knowing where metronidazole sits relative to the other topical treatments your dermatologist might suggest. The three most commonly recommended topicals for papulopustular rosacea are metronidazole, azelaic acid, and ivermectin.

In a randomized trial, 15% azelaic acid gel outperformed 0.75% metronidazole gel on several measures: a 73% mean reduction in inflammatory lesions versus about 56% for metronidazole, along with greater improvement in erythema and higher investigator global assessment scores. Metronidazole’s improvement appeared to plateau after about eight weeks, while azelaic acid continued to show gains through week 15.⁹ A separate trial comparing 20% azelaic acid cream with 0.75% metronidazole cream found similar lesion reduction between the two, though physicians rated global improvement higher with azelaic acid and patients gave it a better overall impression, despite a mild stinging sensation on application.¹⁰ Neither treatment had a noticeable effect on telangiectasia, the small visible blood vessels that bother many rosacea patients.

Ivermectin 1% cream has shown an even clearer advantage over metronidazole 0.75% cream. In the large ATTRACT study, about 85% of ivermectin-treated patients were rated “clear” or “almost clear” at 16 weeks, versus roughly 75% for metronidazole, with ivermectin showing improvements as early as week three.¹¹ A subanalysis of patients with severe papulopustular rosacea found even bigger gaps: about 83% success for ivermectin versus 63% for metronidazole.¹²

So why does anyone still use metronidazole? Cost is a big factor. Metronidazole has been generic for years and is widely available at a fraction of the price of branded ivermectin or azelaic acid formulations. One cost-effectiveness analysis found that metronidazole 1% gel applied once daily was considerably less costly than several other branded and generic alternatives for rosacea.¹³ Metronidazole is also the topical with the longest track record, and many patients and dermatologists remain comfortable with it as a first-line option, especially for mild to moderate disease. European guidelines, including the German S2k rosacea guideline, still list metronidazole alongside azelaic acid and ivermectin as recommended topical treatments.

Adding Oral Medication to the Mix

For moderate or stubborn rosacea that does not clear with topical therapy alone, dermatologists often pair metronidazole with a low-dose oral antibiotic. Two randomized trials tested this combination using sub-antimicrobial-dose doxycycline, a dose low enough that it works through anti-inflammatory mechanisms rather than killing bacteria. Both found that adding doxycycline to topical metronidazole reduced inflammatory lesions significantly faster than metronidazole alone, with visible improvement by about week four.¹⁴¹⁵ In one of the trials, the gains continued even after doxycycline was stopped and the patient continued metronidazole alone. This is a useful finding because it suggests that the oral medication can help break through a flare and then the topical can hold the ground afterward.

Keeping Rosacea Away After It Clears

Rosacea is a chronic condition, and relapse after stopping treatment is common. Metronidazole gel has been specifically tested as a maintenance therapy. In a six-month randomized trial, about 23% of patients applying metronidazole gel relapsed, compared with 42% in the vehicle-only group. Those on metronidazole also had fewer papules and pustules and less erythema relapse over the same period.¹⁶

That said, metronidazole’s maintenance performance does not appear to be the longest-lasting option available. A systematic review and network meta-analysis comparing relapse rates after treatment discontinuation found that metronidazole’s average relapse period was about 12 weeks, compared with 21 weeks for ivermectin.¹⁷ The extension of the ATTRACT trial confirmed this gap directly: the median time to first relapse was about 115 days for patients initially treated with ivermectin compared with 85 days for those who had used metronidazole.¹⁸ If maintenance length is your top priority, ivermectin may be the better tool for that specific job.

Safety and Systemic Absorption

One common concern with metronidazole is whether the topical version carries any of the unpleasant effects associated with oral metronidazole, such as nausea, metallic taste, or interactions with alcohol. The answer is reassuring: minimal metronidazole is absorbed through the skin after topical application, making systemic side effects and drug interactions very unlikely.² This holds true whether you are using the cream or the gel. An animal study that measured blood levels of metronidazole after topical application at various concentrations found that the amount reaching the bloodstream stayed essentially flat regardless of concentration or duration, suggesting a built-in ceiling on systemic absorption through the skin.¹⁹

That study was done on open wounds in animals, which would be expected to absorb more drug than intact human facial skin, so the real-world systemic exposure from treating rosacea is likely even lower. You should not need to worry about the alcohol restriction or metallic taste issues that come with oral metronidazole pills.

How Metronidazole Works on Rosacea

Metronidazole’s mechanism in rosacea is not entirely pinned down, which might seem odd for a drug that has been used on the condition for decades. It was originally developed as an antimicrobial, but rosacea is not a straightforward infection. Current thinking is that metronidazole works through a combination of anti-inflammatory and antioxidant activity. Laboratory data suggest it can scavenge reactive oxygen species, the molecules that drive oxidative tissue damage in inflamed skin.²⁰ This antioxidant action may help explain why metronidazole reduces redness and swelling even though rosacea is not caused by the types of bacteria metronidazole is best at killing.

One reassuring side note: a study tracking the skin and colon microflora of 20 rosacea patients using 1% metronidazole cream twice daily for a month found no significant changes in either the skin or gut microbiome.²¹ Sixteen of the 20 patients improved. This is consistent with the idea that metronidazole is not working by wiping out skin bacteria; rather, it is calming the inflammation and oxidative stress that drive rosacea flares.

Results in Different Populations

Most metronidazole trials have been conducted in predominantly white European and North American populations, which means the evidence base is somewhat narrow. A more recent phase 3 trial conducted in Japanese patients with rosacea tested 0.75% metronidazole gel against vehicle and found strong results: about 72% of patients in the metronidazole group achieved meaningful improvement in both inflammatory lesion count and erythema at 12 weeks, compared with roughly 37% in the vehicle group.²² This trial is significant because rosacea in East Asian skin can present differently, with erythema being harder to detect visually and diagnosis sometimes delayed. The results suggest that metronidazole gel performs well in that population too, which broadens confidence in the drug across skin types.

No head-to-head cream-versus-gel trial has been conducted specifically in non-white populations, so it is not possible to say whether the slight gel advantage seen in the overall evidence applies equally across all skin types. If your skin is darker or your rosacea presents primarily as flushing and burning rather than visible bumps, the choice of vehicle might matter more for comfort than for efficacy, since both formulations address inflammatory lesions more effectively than they address redness or visible blood vessels.